We are committed to fighting inflammatory diseases like IBD. But we’re not alone. We problem-solve across our global offices in 35 countries. We collaborate with external partners to develop innovative therapeutic approaches and aim to further advance the care of patients.
We appreciate the complexities of inflammatory diseases and the difficulty healthcare professionals and patients face every day. Our internal biomarker program is helping us better understand what drives response to help improve outcomes for patients.
In 2015, Gilead entered into a global partnership with Galapagos. In 2019, we further solidified our partnership, entering into a 10-year global research and development collaboration.
Using Galapagos’ unique platform, we’re utilizing disease-related, human primary cell–based assays to discover and verify novel drug targets.
2010
Gilead research efforts expand, evaluating spleen tyrosine kinase (SYK) inhibition and exploring treatments for inflammatory diseases
2014
Gilead and ONO partner to evaluate Bruton’s tyrosine kinase (BTK) inhibitors for B-cell malignancies and inflammatory diseases1
2015
Gilead and Galapagos announce global collaboration to address inflammatory diseases2
2019
Gilead and Galapagos embark on a 10-year collaboration to discover and develop transformative therapies in inflammatory diseases3
REFERENCES 1. Data on file, 2014. 2. Data on file, 2015. 3. Data on file, 2019.
GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
© 2020 Gilead Sciences, Inc. All rights reserved.
UNBP5968 10/20
